Market Overview

Organovo Has Upside To $6/Share, Cantor Fitzgerald Says


In a report published Wednesday, Cantor Fitzgerald analyst Caroline Corner maintained a Buy rating on Organovo Holdings Inc (NYSE: ONVO), while raising the price target from $5 to $6, saying that the company's progress to date has been impressive.

Organovo said that it had booked $1.94M worth of contract revenues to date. Of this, $0.29M has been recognized as revenue through March 2015. "Contract revenues represent customer orders for use of the exVive3D Liver Tissue model for toxicology studies…Based on the recorded revenues and our updated assumptions regarding rate of signing new customers, we have raised our revenues incrementally," analyst Caroline Corner wrote.

In the report Cantor Fitzgerald noted, "Organovo also stated that it has had "multiple customers sign a second contract", which we think is another positive sign this early in the launch. The company mentioned it has liver service contracts with customers in the U.S., E.U. and Asia, and has contracts with multiple top-25 global pharma companies, as well as smaller companies."

In April, the company had announced that it had signed an agreement with Merck & Co., Inc. (NYSE: MRK) for its liver product. Organovo may disclose other pharma partners in the coming quarters. Moreover, the company has a development partnership with L'Oreal SA (ADR) (OTCMKTS: LRLCY), and "we think we could hear updates on the development of the skin tissue product in coming quarters," Corner added.

The EPS estimates for 2015 and 2016 have been raised from $0.5 to $0.6 and from $3.5 to $4.6, respectively.

Latest Ratings for ONVO

Aug 2019DowngradesBuyNeutral
Dec 2018Initiates Coverage OnBuy
Nov 2017DowngradesOutperformMarket Perform

View More Analyst Ratings for ONVO
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Reiteration Analyst Ratings


Related Articles (MRK + LRLCY)

View Comments and Join the Discussion!

Latest Ratings

BKNGConsumer Edge ResearchInitiates Coverage On2,250.0
EXPEConsumer Edge ResearchInitiates Coverage On100.0
TRIPConsumer Edge ResearchInitiates Coverage On26.0
IAreteInitiates Coverage On39.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

5 NYSE Utilities Stocks With The Highest Profit Margin

What's Next For Gold Investors?